SGS opens dedicated extractables and leachables testing facility

By Melissa Fassbender contact

- Last updated on GMT

SGS' new global Center of Excellence for Extractable Studies and Impurities Profiling will span 500 square meters in Wiesbaden, Germany. (Image: iStock:
SGS' new global Center of Excellence for Extractable Studies and Impurities Profiling will span 500 square meters in Wiesbaden, Germany. (Image: iStock:
SGS has opened a new Wiesbaden-based facility to serve as its global Center of Excellence for Extractable Studies and Impurities Profiling as customer demand increases.

The bio/pharmaceutical analytical and bioanalytical contract solutions provider recently announced the opening of the new facility in Wiesbaden, Germany, which will offer extractables and leachables testing to the industry.

The offerings were previously available at the company’s Taunusstein, Germany-based laboratory, approximately 20 kilometers from the new site. However, as Dr. Sheida Hoenlinger, Director, Life Sciences Germany at SGS told us, “market demand​” has necessitated the investment to “enhance capabilities​.”

The new facility will span 500 square meters and will accommodate equipment and instruments transferred from Taunusstein as well as newly acquired pieces, which have been qualified and validated in the new laboratory.

Hoenlinger explained the new facility will feature “enhanced capabilities for extractable studies and investment in equipment for high level impurity profiling which is where we are seeing growing demand​.”

Hoenlinger told us the company has specifically been seeing an increasing demand for “high quality and short turnaround times​.”

We anticipate growing client demand and needs in terms of capacity, quality and delivery time for their extractable and impurity profiling studies​,” she added.

According to the company, all ongoing projects have been transferred to the Wiesbaden facility successfully. The recently freed space at Taunusstein will also allow SGS to expand its quality control release testing capabilities at that facility.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars